We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
+50.4%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.02B
AUM Growth
+$989M
(+49%)
Cap. Flow
+$219M
Cap. Flow
% of AUM
7.24%
Top 10 Holdings %
Top 10 Hldgs %
64.34%
Holding
48
New
8
Increased
9
Reduced
7
Closed
5
Top Buys
| 1 |
Monte Rosa Therapeutics
GLUE
|
+$62.3M |
| 2 |
Biohaven
BHVN
|
+$57.4M |
| 3 |
Janux Therapeutics
JANX
|
+$42.1M |
| 4 |
ADC Therapeutics
ADCT
|
+$40.6M |
| 5 |
Immunovant
IMVT
|
+$37M |
Top Sells
| 1 |
TRML
Tourmaline Bio
TRML
|
+$62.7M |
| 2 |
UPB
Upstream Bio Inc
UPB
|
+$34.2M |
| 3 |
Disc Medicine
IRON
|
+$30.7M |
| 4 |
Cogent Biosciences
COGT
|
+$26.1M |
| 5 |
ATXS
Astria Therapeutics
ATXS
|
+$20.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
1
Abivax
ABVX
$11.7B
| $959M | 31.74% |
7,111,596
| – | – |
|
|
2
Cogent Biosciences
COGT
$6.53B
| $208M | 6.9% |
5,868,162
-930,000
| -14% | -$26.1M |
|
3
CG Oncology
CGON
$6.11B
| $152M | 5.04% |
3,670,206
| – | – |
|
4
Tango Therapeutics
TNGX
$4.53B
| $113M | 3.74% |
12,762,094
+4,225,898
| +50% | +$36.4M |
|
|
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
| $107M | 3.55% |
4,286,480
+1,150,000
| +37% | +$29.1M |
|
6
Dyne Therapeutics
DYN
$3.74B
| $90.3M | 2.99% |
4,615,144
| – | – |
|
|
RAPT
7
DELISTED
RAPT Therapeutics
RAPT
| $87.5M | 2.89% |
2,582,408
+946,133
| +58% | +$29.4M |
|
8
Tyra Biosciences
TYRA
$1.88B
| $76.2M | 2.52% |
2,898,103
| – | – |
|
9
Amylyx Pharmaceuticals
AMLX
$1.9B
| $75.4M | 2.5% |
6,243,812
| – | – |
|
10
Savara
SVRA
$1.15B
| $74.5M | 2.47% |
12,362,205
| – | – |
|
|
11
Monte Rosa Therapeutics
GLUE
$1.94B
| $72.5M | 2.4% |
+4,622,151
| New | +$62.3M |
|
12
Ocular Therapeutix
OCUL
$1.99B
| $69.7M | 2.31% |
5,740,231
-377,001
| -6% | -$4.58M |
|
13
Dianthus Therapeutics
DNTH
$5.29B
| $69.1M | 2.29% |
1,676,624
| – | – |
|
14
EyePoint Inc
EYPT
$1.1B
| $65.3M | 2.16% |
3,572,335
| – | – |
|
15
Structure Therapeutics
GPCR
$3.29B
| $64M | 2.12% |
920,857
-142,143
| -13% | -$5.8M |
|
16
Spyre Therapeutics
SYRE
$8.24B
| $62.3M | 2.06% |
1,900,582
+800,000
| +73% | +$20.9M |
|
17
Fulcrum Therapeutics
FULC
$235M
| $59.4M | 1.97% |
5,250,000
| – | – |
|
18
Liquidia Corp
LQDA
$6.7B
| $59M | 1.95% |
1,710,084
| – | – |
|
|
19
Biohaven
BHVN
$2.16B
| $52.3M | 1.73% |
+4,631,317
| New | +$57.4M |
|
|
20
Immunovant
IMVT
$7.98B
| $42.2M | 1.4% |
+1,660,933
| New | +$37M |
|
21
Kodiak Sciences
KOD
$2.57B
| $40.4M | 1.34% |
1,445,538
+300,000
| +26% | +$6.14M |
|
|
22
ADC Therapeutics
ADCT
$160M
| $40.2M | 1.33% |
11,390,175
+10,000,000
| +719% | +$40.6M |
|
|
LBRX
23
LB Pharmaceuticals
LBRX
$896M
| $38.8M | 1.29% |
1,745,015
-1
| -0% | -$17 |
|
24
Xencor
XNCR
$1.07B
| $37.5M | 1.24% |
2,452,138
| – | – |
|
25
Revolution Medicines
RVMD
$38.1B
| $34.8M | 1.15% |
436,473
| – | – |
|
Similar funds
DILIC
IIM
KCM
ACM
BCP
AL
ACA
MSC